Dapagliflozin cuts HF hospitalisation in carriers of cardiomyopathy genes, Nature study suggests

The number needed to treat for the gene carriers was 7.7, compared with 100 for non-carriers. The SGLT2 inhibitor dapagliflozin is associated with a 13% absolute reduced risk of heart failure–related hospitalisation in patients with genetic